10th MASH Drug Development Summit 2026
Hosted by Hanson Wade
- 15 – 17 September 2026
- The Colonnade Boston, Boston, United States of America
- Health SciencesPharmacy & Pharmaceutical Sciences
Let others know you'll be there. This does not register you for the event.
Registration
Event has endedRegistration is handled by the organiser
Fees are listed on this page
View registration detailsKey facts
10th MASH Drug Development Summit 2026 is a summit held 15 – 17 September 2026 in The Colonnade Boston, Boston, United States of America, organised by Hanson Wade.
- Dates:
- 15 – 17 September 2026
- Format:
- In person
- Venue:
- The Colonnade Boston, Boston, United States of America
- Subjects:
- Pharmacy & Pharmaceutical Sciences
- Organiser:
- Hanson Wade
- Official website:
- mashdrugdevelopmentsummit.com
The 10th MASH Drug Development Summit is the premier industry forum dedicated exclusively to advancing MASH therapeutics from discovery through clinical development. Organised by Hanson Wade, the event takes place from September 15–17, 2026, at The Colonnade in Boston, MA. Bringing together senior leaders across discovery, translational science, clinical development, biomarkers, and regulatory strategy, the summit uniquely combines a focus on human-relevant preclinical models, non-invasive biomarkers, AI-enabled pathology, and advanced combination strategies to tackle the evolving post-approval landscape of metabolic dysfunction-associated steatohepatitis.
Conference theme
Programme highlights
View full programmeKeynote speakers
View programmeKeynote
Scientific Director & Associate Research Fellow, Pfizer
Targeting Thyroid Hormone Receptor-Β Pathways To Reduce Liver Fibrosis, Improve Metabolic Function & Enable Durable Clinical Benefit In MashKeynote
Senior Director, Metabolic Diseases, Insitro
Integrating AI/Ml With Disease Biology To Identify Differentiated Novel Mash TargetsKeynote
CEO & Founder, Viscient Biosciences
Developing MASH Therapeutics Utilizing Complex 3D Human In Vitro, In Vivo & Ex Vivo Models to Validate MASH Therapeutic Efficacy Across SystemsKeynote
Vice President, Discovery Biology, Sepia Therapeutics
Exploring Epigenetic Editing Approaches to Target Fibrotic Drivers, Enable Precision Modulation & Expand Next-Generation MASH Therapeutic StrategiesKeynote
Chief Executive Officer, Cirius Therapeutics
Tailoring Combination Strategies to Address Disease Heterogeneity & Improve Therapeutic OutcomesKeynote
Founder, Director & Senior Scientific & Medical Advisor, Madrigal Pharmaceuticals
Adapting Mash Development Strategies Within An Evolving Treatment Landscape To Define Clinical Value, Enable Differentiation & Establish Future Standards Of Care2 conferences on kongre.netKeynote
Medical Director, Global Clinical Development, Late Stage Cardiovascular, Renal & Metabolism, AstraZeneca
Advancing Genetically Validated Targets & Combination Development Strategies to Improve Therapeutic Precision, Enable Differentiation & Support Long-Term Success in MASHKeynote
Vice President, Head of Clinical Development, Rivus Pharmaceuticals
Leveraging an Energy Expenditure Mechanism to Drive Liver-Targeted Reductions in Fat and Inflammation, the Primary Drivers of MASHKeynote
Associate Director, Clinical Research, Akero Therapeutics
Demonstrating Fibrosis Regression Through Non-Invasive Assessments in the Ph2b SYMMETRY Trial of Efruxifermin: Advancing Development in Compensated Cirrhosis Due to MASHKeynote
Associate Professor of Medicine & Director, Liver Fibrosis Research, Beth Israel Deaconess Medical Center
Targeting Cirrhosis & Fibrotic Complications To Improve Translational Relevance, Enable Late-Stage Intervention & Expand Therapeutic Impact In MashKeynote
Director, Translational Science, Metabolism Corcept Therapeutics, Corcept Therapeutics
Identifying High-Risk Patient Populations Through Clinical & Biomarker Insights to Enable Earlier Intervention & Improve Long-Term Outcomes in MASHKeynote
Faculty, Harvard Medical School and Mass General Brigham
Neuro-Immuno-Metabolic Regulation of MASH ProgressionKeynote
Chief Scientific Officer, Vertero Therapeutics
Targeting Bile Salt Hydrolase with the Oral Small Molecule VT-6382 as a Novel and Differentiated Approach to Treating MASH and Liver Fibrosis
Speakers
View all 22 speakersOrganiser and contact
Contact
- Event secretary:
- Anna Westgate-Maher
- Email:
- [email protected]
Advertisement
Related events
- 4th Covalent Drug Discovery & Development SummitBoston, United States of America20–22 Oct 2026
- 9th TPD & Induced Proximity SummitBoston, United States of America26–29 Oct 2026
- 3rd Raw Materials for Cell & Gene Therapy SummitSan Diego, United States of America26–28 Oct 2026
- 5th Process Monitoring in Pharma Manufacturing SummitBoston, United States of America27–29 Oct 2026
- 2nd T-Cell Engager for Autoimmune Disease SummitBoston, United States of America27–29 Oct 2026
- The 4th International Human Gene Therapy ConferenceBoston, United States of America28–30 Oct 2026
